Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 0,44€(−49,43%). Der Median liegt bei 0,44€(−49,43%).
Kaufen | 3 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / May 16, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. "Our company remains focused as tightly as ever on neuro-oncology drug development.» Mehr auf accessnewswire.com
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing of its "reasonable best efforts" public offering with a single healthcare focused institutional investor for the purchase and sale of 3,952,570 shares of common stock of the Company (the "Common Stock) (or common stock equivalents in lieu thereof), at a purchase price of $1.265 per share of Common Stock. The Company further agreed to issue to the investors Series F Common Stock purchase warrants to purchase up to 3,952,570 shares of Common Stock (the "Series F Warrants").» Mehr auf accessnewswire.com
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM) Management releases "What This Means" segment discussing the receipt of Orphan Drug Designations for TPI 287; Access here HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the successful transfer from Cortice Biosciences, Inc. of Orphan Drug Designation for TPI 287. The U.S. Food and Drug Administration (FDA) previously granted Orphan Drug Designations for TPI 287 in treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.» Mehr auf accessnewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −3,98 Mio | 21,05% |
EBITDA | −4,01 Mio | 22,33% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 4,80 Mio€ |
Anzahl Aktien | 5,46 Mio |
52 Wochen-Hoch/Tief | 393,16€ - 0,68€ |
Dividenden | Nein |
Beta | 0,78 |
KGV (PE Ratio) | −0,17 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,25 |
KUV (PS Ratio) | 1.739,47 |
Unternehmensprofil
Name | CNS PHARMAC. INC. DL-,001 Aktie |
CEO | John Michael Climaco Esq., J.D. |
Mitarbeiter | 4 |
Assets entdecken
Shareholder von CNS PHARMAC. INC. DL-,001 Aktie investieren auch in folgende Assets